Allogeneic HB-adMSCs not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Acute Kidney Injury
- Main trialPhase 1/2
- “This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).”In the company’s words, NCT06654193 on ClinicalTrials.gov
Other drugs for Acute Kidney Injury
- QRX-3Ebima Clifford Okundaye · Phase 2/3
- PrismocitrateVantive Health LLC · Phase 3
- AZD4144AstraZeneca · Phase 2
- LSALT peptideArch Biopartners Inc. · Phase 2
- R2R01River 2 Renal Corp. · Phase 2
- CSL889CSL Behring · Phase 2
Coming up1
- 1 Jan 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 1 Jan 2028 | Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury | |
| Phase 2Completed | 3 Oct 2025 | Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026